Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2126 - 2150 of 14949 in total

Danaparoid

Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … The active constituents are heparan, dermatan and [DB09301] [T28], and they are isolated from the porcine ... in the United States however it is available in several other countries including European countries and ... Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Sargramostim

Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Elotuzumab

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab...
Approved
Matched Description: … Food and Drug Administration. ... a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and ... complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Fruquintinib

Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate ... Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis ... Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient …

Luspatercept

Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and ... erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins ... Intracellular Signaling Peptides and Proteins …

Ocriplasmin

Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved
Matched Description: … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Remoxipride

Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Categories: … Benzamides and benzamide derivatives …

Apalutamide

Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Description: … It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription ... risk for metastases and death [A31846]. ... Apalutamide displayed good tolerability and safety profile in clinical studies. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …

Patent Blue

Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …

Peginterferon beta-1a

Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … , disrupting communication between the brain and other parts of the body. ... Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system ... fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Thrombin

Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational
Matched Description: … coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and ... Patients who are know or suspected to have antibodies to bovine thrombin and/or bovine factor V should ... These antibodies may subsequently cross-react with endogenous human factor V and lead to its deficiency …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Mogamulizumab

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically...
Approved
Investigational
Matched Description: … antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and ... Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare ... Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly ... [A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), ... Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... associated with comorbidities such as hypertension, diabetes, and depression. …
Matched Categories: … Hypnotics and Sedatives …

Nabumetone

Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval ... [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Vemurafenib

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Talimogene laherparepvec

Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within...
Approved
Experimental
Investigational
Matched Description: … It specifically replicates within tumor cells and causes lysis. ... laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and ... that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Tinzaparin

Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … It is an anticoagulant and considered an antithrombotic. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Levomilnacipran

Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …

Quinethazone

Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia. …
Matched Categories: … quinethazone and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Sulesomab

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Inflammation and Infection Detection …

Valoctocogene roxaparvovec

Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active...
Approved
Investigational
Matched Description: … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for ... hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and ... A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Beremagene geperpavec

Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy …

Ethanolamine oleate

Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Approved
Matched Iupac: … (9Z)-octadec-9-enoic acid; 2-aminoethan-1-ol …
Matched Description: … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, …

Cenegermin

Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and ... L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and ... Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
Displaying drugs 2126 - 2150 of 14949 in total